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Over the past severa l years there has been a steady increase in the incidence of 
immunologically compromised patients. This has been the result o f both che mical agents. suc h as 
those used in cancer chemotherapy, and biological agents such as HIV, the cause of Acquired 
lmmunodefeciency Syndrome (AIDS). The increase in immune-suppressed patients has lead to an 
increase in li fe -threatening mycoses requiring treatment with antifungal agents. Pharmaceutical 
companies have increased research for the development of new antifungal i.lgents which are more 
effective and less toxic than those th at are currently used. Several resea rchers have reported on 
antifungal agents that demonstrate both positive and negative effects on the immune syste m. 
Because antifungal therapy relies on host immune defenses in eliminating diseases, more em phasis is 
being placed on how antifungal agents interact with the immune system. The purpose of this study 
was to eva luate the effects of Ketoconazole, ltraconazo le and Fluconazole on T- and B-cell 
prolife ration and natural killer ce ll ac tivity using norm al, cyclosporine·compromised and 
cycloph osphamide·compromised immune models in mice. T and 8 ce lls obtained from the spleens of 
Balb/c mice were mitogen st imulated and grown in the presence of 0, l, 2, 4, 8 and 16 1-'g/ ml of these 
3 antifunga l agents. Ce ll proliferarion was determined by the uptake of 3[HJ-thymid ine and was 
measured as counts per minut e. NaiU ral killer ce ll activit y was meas ured by the release of 51 -sodium 
chromat e (5 1Cr) in to the supe rn ata nt by 5 1Cr-labe led Yac cells. Ket oconazole ca use d a significa nt 
reduction in ce ll proliferation in all immune models in both T and 8 cells . ltracon<Jzole ~tl so 
significantly inhibit ed ce ll proli fe rat ion in all models in both T and B ce lls as well as natura l killer 
(N K) ce ll act ivi ty in the immune-normal model. Viability studies on mitoge n-stimu lated l ymphoc~1 es 
suggest that th e inhibitory effects of Ketocona zole and Itraco nazole on lymphocyte proliferation arc 
due ro toxic e ffects. Fluconazo le appc.:us to have few if any inhibirory effects on either cell 
prolifera tio n or natural killer cell activit y. 
(65 pages) 
INTRODUCTION 
Over the past several yea rs the incide nce o f life~t h rcalen i ng fungal infectio ns has been o n the 
ri se. This ca n be a ttributed to orgctn transplant ation, che mo thera py fo r the tre.1 tm cnt o f cancer ;111d 
thc AIDS epidemic. Th e first heart transplan t was pe rform cd almost 20 y<.;ars ago. The patient di~.:d 
18 d:1 ys later beca use of an infection that his immune system \'-':ts unable to e liminat e. This w;..a s :1 
result o f immunosuppressive thcrt~py used to fi ght rejection of the heart (9). Despite the adven t of 
cydosporinc in the late 1970s, infection s resulting fro m immunosuppression arc s till a probkm. 
Cancer chemothcrary us ing such drugs as cyclop hosphamide also has a signilica nt im(Xlc t on th e 
immune syste m, a nd many c:-~nccr patients die from th e infect ions br ' light about by th~ 
immunosu ppression rathe r than from the ca ncer itself. O ver the past few years the A IDS c pidcmiL 
has increased ;tt an a larming r~ilc. The Ce nt e rs for Di se .:1 sc Cont w l in A tl an ta re ported that as ol 
.lul v, 1 9~9 over 100,000 cases of A IDS had been re ported and ove r 59,000 A IDS-re lat ed deaths had 
occurred ( 13). All o f tln;~c factor s have res ult ed in the increase o f diseases that have ra rely been seen 
or have no t been conside red life threaten ing. A ntifunga l the rapy has no t bee n a fie ld o f grc~• t 
resea rch int e nsity bu t is becoming of much grea te r im portance i) S th e need for new and more 
dfcctivc age nt s has become evide nt ( 1-t). Inte rventio n in the disease process by an a ntimicrnhi:d 
age nt still re lics heavily on the host immune system to aid in co mbating and clea ring infections. In 
a nti funga l the ra py, host immunit y is even mo re impo rt an t because most an tifungal agen ts arc 
fu ngis tatic and no t fungicidal. The impo rta nce of developing a ntimicrobial age nts th at do not impa ir 
th e immune sys te m is g rowing, especia ll y for pa tients whose immune syste ms arc a lready impaired . 
The objective o f this research was to study the e ffect s of Kc toconazole, a current ly used antifungal 
age nt , a nd 2 new compounds that arc now in clinica l trials, Fl uconazole a nd ltraconazole, in h01h 
immune-norma l a nd immune-compromised mode ls. 
REVI EW OF LITERATURE 
Fungal lnfel'tions and Hos t Immunity 
In order for fungal o rganisms, the majo rit y o f wh ich are oppon unis tic pathogens, to c~nJSl' 
disease they must cvndc elimination hy the immune syste m. It is generally agreed that ccll-rnedi~ttcd 
immunity (CM I) is o ne of the most effective mechanisms of resis tance to fungal infections (.':,21). 
Mechanisms against such o rganisms :lS Candida albicans a rc believed to involve specific T cells (R). 
Evidence support ing these beliefs lies in the fac t that patient s h<tving recurrent fu ngal infections often 
display defective delayed hypersensitivit y, as demonst ra ted with skin tests. Patients with A ID S whll 
lack certain T-ccll funct ions often h;tvc fungal infections such as candid iasis and cryptococcosis. On<:c 
specific T cells have been ac tiv;.tt ed. they produce soluble factors which stimubt c non·spccili l: 
immunity ,·ia polymorphonuclear le ukocytes (PMN) and mononuclea r ph<tgocytcs, which p lay J.ll 
important ro le in e liminating the organ isms from the hos t. Ccll·mc diat ed immunity, in particubr 
natural killer cell activity, is be lieved to be v<.:ry important against Crywcoccal infec tion _, (2 1) . It i~ 
when these lines of defense arc broke n down, through e ithe r chem ica l or biological means. tkLt 
se rious J.nd rot c ntially fata l fungal infections can occur. 
Immunosuppres s ive Agents 
As stat ed ea rlier , several drugs frequen tly used in cance r therapy and o rgan transplanta tion 
produce a markeU su ppressive effect on the immune syste m. Two common drugs useU fo r thl' SL' 
purposes arc cyclophospha mide a nd cyclosporine. 
Cyclophosphamide. Cyclophosph.:tm ide is used in the trcJ.tment o f severa l malign:liH.:ics 
includ ing malignant lymphomas, multiple myeloma a nd leukemias. It in terferes with the growth or 
susceptib le neoplasms and, to some exten t, normal tissues, although the mechanism o f act ion of this 
drug is no t known . One o f th e expected e ffects o f cyclophosphamide trea tm en t is leukope ni a which is 
used as a g uide to therapy. Therapy includes an intravenous induction dose of -+0·50 mg/ kg and then 
either daily doses of l-5 mg/ kg or weekly doses o f l0-15 mg/ kg (3). 
An int e res ting effect that cyclophosphamidl: can havl: unde r certain conditio ns is to actual I~ 
increase res ista nce to infections. Francesco Bistoni and his associates perform ed seve ral expe rim e nt s 
wit h cyclophosph amide in vil 'O and in l'itro and found that fo r the first 6-10 dJys afte r treatme nt with 
cyclophosphamide, the re was a s ignifica nt increase in susceptibility to infec ti on fo llow·cd by a p.:r ind 
fr om 12-24 days afiL:r treatm e nt in whi ch there w~1 s a s ign ificant rise in res istance to infection b~ 
Candida species (7). They fo und th e res is tance was due to, at leas t in pa rt , a lymphocyte \~ ith 
cxce pti1mJ. l killing abilit ies toward Candida species which was clearly dis tinct fro m N K cells . Thcrl' 
was Jlso an increJsc in the NK-cc lllyt ic acti vi ty JS we ll as above norm.1l numbe rs o f pe riphe ral blood 
P,\IN's. 
Cyclnsporine. Cyclosporinc is a cyclic polypept ide immunosuppressive drug which j, 
produced as a mcia bolite o f the fungu s spec ies To~'pocladium i11j7atum G.-tm s. It is a pot e nt agent 
that suppresses ce ll-m ediate d reactio ns such as .1l logrart rejec tion, dclayeU hype rse nsitivity and 
e xpcrimcntJI al le rgic c nceph<.~lom yel iti s. Th e mechanism o f acti on is not known at this tim e, but 
experime ntation suggests that cyclospor ine in terferes with the Go o r G 1-phase o f ce ll grmHh in 
immun ocompe te nt lymphocytes. The lymphoqtes th at seem most affected by cyclosporinc are the T-
hc lpcr cells anU to a lesser extent T-suppressor cells. Cyclosporin c al so appears to inhibit production 
and release o f lympho kines including int c rlukin-2 (T cell growth factor ) (4). Beca use of the pol L' ncy 
o f the drug it is o nly to be used by physic ia ns wi th expe rie nce in immunosuppress ive thera py wit h the 
p;:~ticnts being close ly monitored for toxicity. Kctocon<~ zolc .1nd Amphotericin 8 increase plasma 
levels of cyclosporine by dec reasing metabolism of the drug (5) . 
Ant ifunga l Agents 
In cases o f life -threatening fungal infec tions, Amphoteric in 8 is usually the drug of choice. 
eve n though the drug itself is highly toxic. Patients receiving the drug may develop perm:.tncnt kidn ~y 
damage (5). Pharmaceutical companies a rc now developing compounds which will provide an 
a lt ernative mea ns fo r treating life-threaten ing mycosis with fewer o r less severe tox ic side effects. 
Kctoconazolc is a more recently developed a ntifunga l agent that can be used as an altcrmtti\·c to 
Amphotericin B in some cases. ltraconazolc and FluconJzole arc co mpounds that are now in dinic:d 
trials and offe r mu ch hope as an alterna tive to treatment wit h Amphotericin B. 
Ketocon:~zole . Kc toconazolc is a n anti fu ngal agent that falls into the class known a:-. 
imicbzolcs. The e ffec ts of Ketoconazolc on fungi are primarily fungistatic. Ke toconazole, for the 
treatment of candidiasis, is given as a s ingle daily close of 200 mg wi th treatment bsting as short a:-; I 
wee k a nd can be as long as -l weeks o r more in dcrmatophytic infections. Kctoconazolc rcacht.::-. ~~ 
mean pea k pbsma concen tration of approximate ly 3.5 J.Lg/ ml within 1 to 2 ho urs afte r administ ration . 
It is indicat ed in th e trea tm ent of the following infections: cand idi as is, chronic mucocutane ous 
can didiasis. ora l thrush, candidur ia, b!Jstomycosis, coccidioido mycos is, hi stoplasmos is, 
ch ro momycosis a nd pa racoccid ioido mycos is. H c patoxicit y occurs in about I 10,000 pa tie nt s, and 
tht.:rc have been a few G ISCS of death re late d to treatment wit h Kctoconazolc (6). 
Although the mechanism of action of Kctoconazo le is not precisely kn own, cxpcrimcnt~ll 
results indicJt e that it prevents the demethylmi on of lanosterol in fungi (t0,12,L8,2-l). La nos terol i:-. 
the precursor to ergosterol, which is the major mem brane s terol in fu ngi. \Vitho ut ergosterol the 
ce ll 's permeabili ty increases, which inhibits g ro\vth o f the orga nism (12,17). In mammalian cells 
Kc toconazole has a lso been shown to inhibit the demethybtion o f lanoste ro l, which in turn inhibit s 
cholesterol synthesis. One theory for the inhibit o ry effects which Ketoconazolc has on the imm une 
syste m in vitro is tha t most cells arc able to usc exogenous cho les terol acquired from serum , but 
ce rt ain ce ll s, such as lymphocytes, require endogenous cholesterol prior to proliferation (12) . 
Th omas Buttke and Stanley C hapman pe rform ed ex periments to dete rmine the effect or 
Kctoconazole o n mitogen-induced DNA synthesis and cho lesterol biosynth es is in lymphocytes (12). 
Human and mouse splee n ce lls were stimulat ed by phytohemaglutinin (PHA), Staph auretn or 
lipopolysaccha ride ( LPS ) and were in cubated in the presence o f va rio us concentratio ns of 
Ke tocona zole. During the last l6 to 18 ho urs of incubati on, mit ogen·induced DNA synthesis was 
measured by the addition of 0.5 !LCi of tritiated thym idine. At the e nd of the incubation period the 
ce ll s we re harvested on glass fiber fillers, and the amoun t of incorpo rated triti ated thymidine was 
measured with a scintillation co unte r. A t Ketoconazole conce ntr:.~ti o n s of 10 .Ug/ ml , DNA synth c:-. i ~ 
hy lym phocytes was 80-90% inhibit ed. Ste ro l synthesis was measured by incubating miwgcn-
st imu latc d human a nd mo use lymphocytes fu r 2-l ho urs fo llo ,vc d by the additio n of 10 ,UCi o f 
[ l-t C [acctat e and co ntinuing incubatio n fo r an additional 6 ho urs. Lipids we re ex tracte d from the 
ce lls ami we re quantified by liquid scintillation counting. It was shmvn that a t conce ntrati ons o f I 
.Ug/ ml , we ll within the rape utic leve ls, 80-90% inh ibition o f cho leste ro l synthesis was obscn ·ed. 
In ce ll -prolife ra tio n ex pe rim e nt s ve ry s imilar to those of Buukc . D .S . Se nio r and .J.T.B . S h ~ t \\ 
<ll Pfize r l;)hs dc mo nstr<tted that Ke tocnnaz0le has an inhibit o ry e ffe ct o n hbstogencsis {lf 
lymph ucytc:s at leve ls as low as 1 J...L g/ ml (22). Th ey also per fo rm e d e xpe rime nt s to ascertain tlu.: 
cfft:cts of Ke toconazole on the Candida- killin g activity o f Prvt N's using a rJdio labe l re le ase assJy. 
Candida albicans blastos po res were radio labe led with 3H -urid in c fo r 60 minut es and we re the n 
inc ubat e d in the prese nce of human PMN le ukocytes at a t:lrgc t:cffcctor ce ll rati o o f 3: I. Following a 
(,0- rninut c incuba tio n, the PMN 's we re lysed with sodium dcoxyc.:hobt c to release labe l fro m c ng ulful 
bb s tospores. Supe rn;.H ::mt fro m the cult ures was count ed o n a liquid scintilla tion counte r to 
de te rmin e the exte nt o f candida blnstospore lys is. Ke toco nazole cause d s ignifi ca nt reductions 111 
blastospore killing at 10 1-Lg/ ml. 
Studies were conduct ed a t the Me rck rnstitut e fo r The rape utic Research to de te rmine the 
effect o f nntifunga l agents on the che miluminescence (CL) respo nse (1,2) . Mo use splee n ce lls were 
co llected and adjusted to 1 X 107 cells/ml and ~70 1-LI were aliquotcd into lum acuvettes. Aft er th e 
addition of 10 J...LI of known concentrations of various antifungal nge nts, including ke toconazole , the 
ce lls were incubat ed for 30 minut es at 37C. Aft er th is incubation, lO 1-LI of luminal (1 mg/ ml) was 
adde d, and the che miluminescence respo nse was measure d every 20 seconds fo r 30 minutes. It was 
fo und that at concentrations as low :..~ s 3 J...Lg/ ml, Ketoconazolc inhibited the CL respo nse. The CL 
response measures light emitted by phagocytic cells upon producing oxygenated compounds, such as 
hydroge n pe roxide a nd superoxide, during the respiratory burs l. 
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D../. Marmer and his colleges studied the effects o f Ketoconazo lc on lymphocyte cel l 
vi:1bi lity, chcmot;:Lxis, and killing by cht.: milumincscencc Li9). Cel ls that were obtained from donors 
rccci\·ing antifungal the rapy at ti mes correspo nding to peak plasma levels o r cells that wen.: 
pretreated with antifunga l agents were used in the various assays. Ncutrophils treated with 
Kc tocona zolc were pbccd in wells. cut in an agarosc plate, and tes ted for th e ir chemota ctic response 
to zymos~m-act i vatcd au to logous serum . Afte r a 2 hour incubation, the plates we re sta ined a nd 
assessed for the numbe r of ce ll s th at migr~H ed in a si ng le pbnc. Experime nt s si milar to th ose 
performed by th e Me rck rnstitutc we re carried out to dete rmine the C L response. Neutrophi ls 
~.xposcd to va rious conce ntrations of Kctoconazo le for 3 hours were assesse d for viability by exclusion 
of trypan blue. Phagocyt ic bactericida l acti\"ity was de te rmined hy incubating cffcc10r ce lls with 
Swphylococcus aureus, after which the h~tcteri.:t were plat e d o ut and colony counts were performed. 
KLtoconazolc was found to have no e ffect on any of th e parameters meas ured. Some of these 
!indings are in d irec t conOict with those re po rte d earlie r, which indicat es possible differences in 
procedures or differe nces in assays performed. Most experim en tal evide nce support the conclusion 
that Kctoconal'o lc has some nega tive effect o n the immune system. 
Johnson ct al. exam ined th e effect o f Kctoconazolc on phagocytosis a nd killing of C. 
albicans, as we ll as germ tube elongation of ingested blas10s po rcs us ing human nc utrop hils (17). Th ~.: 
pa ram ete rs we re assayed using 3 diffe re nt tests in wh ich: 1) Drug was added s imuhaneo usly tu the 
phagocytes and blas tospores , 2) Phagocytcs were pre treat ed with drug and 3) Blast0<pores were 
pretreated with drug. Germ tube fornwtion was measured <.Jt 2, 4 and 6 hours using a microm e tt:r 
eye piece. It was found that Ke toconazolc has no s ignificant effec t on phagocytosis o r the killing of C. 
albicans. Ketoconazole did no t effect ge rm tube formJti on of e ithe r ingeste d o r non·ingi.:stc tl 
hlastospores in stntins o f C. a/bicafls that were resistant to azoles, but had marked reduction in germ 
tube lengths in blastospores sensitive to azolcs. 
Van Rcnsburg and associat es at the University of Pre toria, South Africa performed se\'e ral 
experiments to de termine the effect o f Kc toconazolc on ne utro phil random migration , chemotaxis. 
phagocytosis. and post-phagocyti c hexose mon ophos phJt e shunt ac tivity in l'itro (25). Ncutrophil.s 
were obtained from hepa rin ized blood o f 6 adult subjec ts a t 2 and 96 ho urs a fter ini tiation of 
tr c~1tm c nt. consis ting o f 200 mg of Ket oconazole twice dail y. Ke toconazole ca used an increase in 
che mot axis in ncutrophils incubat ed in the presence o f e ither se rum activated with bact er ial 
e ndotoxin o r synthe tic che motacti c tripe ptide at 2 hours afte r trcatm e nl. H owever, this increase was 
nnt obscr\'cd a t 96 hours after initiation o f treatm ent. Kc toconazolc did not affect the phagoc~ti c 
~lc ti\'ity o f neu trophils incubated in the presence o f C. a/bicans. Likc\v· ise, Ke toco nazo lc had no dft:ct 
on hexose mo no phosphate shunt (HMS) activity wh ich w:1 s measured by th e me tabolism of D-[1 · 
1~C[ glucose labe led at the C-l position. 
Gergely et al. studied the effect o f Ke toconazolc o n mitoge n-induced b lastogenesis, 
:mtibody-dc pc ndent cytotoxicit y. n:1tur:d-kille r ce ll activity and the nmdom migr~1ti on of human 
leukocytes ( l (l) . Hum an pe riph c rnl blnod lymphocy1 cs we re obtained fro m human do nors. 
Ketocona zo le red uced the uptake o f 3[H]thymidin t; by lymphm:yres stimui<Jtcd with 
phyto hc maglutinin at levels as low as I J.Lg/ml. A t concentrations grea ter than l J.Lg/ml, 
Kc toconazo lc decreased antibody-tlc pcndcnt cell-mediat ed cytotoxicity of human mononuclear ce ll s 
agJinst 5 1C r-bbc lled, antibody-coated chicken red blood ce ll s. Kctoco nazolc <:~ t leve ls greater than I 
!'g/m l also decreased natural kille r-ce ll ac tivity agai nst 5 1c r-labclled K 5G2 target cells. 
Kc toconazole a lso reduced the amount o f migra tio n of leukocytes at levels as low as 1 J..Lg/ml. 
ltraconazole. Itraconazole is a new antifungal age nt currently being tes ted by Jansse n 
Ph:lrrnaceuticals, the same company th3t manufactures Ke toconazolc. It is classified as a triazolc 
an tifungal agent. Pre liminary indicat io ns are that it mig ht be mo re effective and less toxic than 
Ke toco nazolc (10, 15). It has the re lative ly lo ng half-life of I Jay in man with peak plasma levels, 
fo llowing a 100 mg oral dose ranging from 0.2- 0.6 J..Lg/ml, a lthough levels in ti ss ues ca n be up to 1-t 
times the leve ls achieved in plasma (15). Like Ketoconazn lc, ltraconazole's mode of ac tion lies in it s 
abil ity to block the cytochrome P-450 de pendent deme thylatio n o f lanosterol ( 10). J a nssen has 
reported that this inh ibition occurs in fungi a t extremely low (nM) conce ntratio ns. Pa tient s rece iving 
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up to ...JilO mgj d:ty for 3 months had no in creases in cholesterol levels. Oth er studi es, perform ed with 
rat s, indi c;uc th:..~t lcn.: ls as high as 40 mg/ kg do not effect cytoch rome P-...J50 dcpcm.lcnt choleste rol 
synthesis in li\·cr mi crosomes (10). Beca use it is a relatively new compound, lillie resea rch has been 
don e to cvn luat c its effect on the immune system. In th e sa me experiments perform ed by th e Mcrck 
Institut e for Th cr.:1pc utic Research with Kctoconazolc, ltraco nazo lc was determined to inhibit th e CL 
response :tt '20 J..Lg/m l. which is about 30 t im es highe r than plasma levels and 2-3 times more th:111 
lc\·d s achieved in ti ssue (1). In the previously described expe rime nts pe rfo rm ed by Johnson. 
lt r: J COn<~zolc showed no signifi ca nt effect on phagocytosis or killing of C. albicans blasrospores ( 17). 
Fluconazolt• . Flucona zole is a newly synth esized antifunga l agent with a bis· triazok 
structure. The drug was developed and is currently being tes ted by Pfize r. Like OLher imidazole· 
rcl ~ 11 ed compounds, the mode of <Jction appears to be the preve ntion of the Cl4 dcmcthybti on ol 
l:uwsh.: ro!, wh ich is a precursor for e rgoste rol, the major sterol in funga l membran es (20). Th e 
compound is one of the few antifungal agents that is wat er soluble, and is therefore capable of being 
ad ministered ora lly or parentally. It h:1s <.1 half· life of 25 hours in man. Peak serum leve ls of 
approxim;ncly I J.Lg/ ml are achieved about t hour aflcr .ad minist rmion of a 50 mg oral dose. (Ll ). r\.c; 
with lt raconazolc, little has been done to evalu;He the effects of Fluconazole on the immune system. 
In the sam e studies discussed earlier, resea rchers at the Me rck Institute for Therapeutic Research 
determin ed th ;1 t 111 levels up to 20 J.Lg/ ml, Fluconazole had no significant effect on the CL response in 
mou se sp leen ce lls (1). In the previously discussed experiment s performed by Pozer Central 
Resea rch, which compared Ketoconazol e with Fluconazole in mouse lymphocyte prol iferation and 
Candida bbstospore destruction, they found Flucona zole to hnve no significant effect in either of the 
2 i!Ssays performed. Ketoconazole reduced proliferat ion and killing by human polymorphonuclea r 
leukocytes (22). 
Amphotericin H. As mentioned before, Amphotericin B is the drug of choice in life 
threatening ci rcu mstances. Amphotericin B is an antifunga l agent developed by E.R. Squ ibb & Sons, 
In c., Princeton, New Jersey. The antibiotic is derived from a strJin of Streptomyces nodosus, and is 
no t soluble in Wil le r. The drug as suppli ed by the manufJcture r, is solubilized by th e addition o f 
sod ium dcsoxycholate . This fo rms a co llo ida l mixture upo n the add ition o f wate r which all ows it to 
he g i\·c n pa ren te ra lly. This compo und has aCLi vity against a \vide range of fungi with in \'itro M IC 
\'alues be tw~c n 0.03 a nd J.O ,U.g / ml. Amphotericin B is e ith e r fungi static o r fungic icbl depending 
upo n th e leve ls achi eved in body nuids a nd upon the susceptibilit y o f the o rganism. Th e probabl e 
mode o f actio n of A mphote ricin B is binding to me mbra ne ste ro ls which creates a change in the 
me mbra ne pe rm eability a nd results in lea kage. Mamm a lian ce lls also contain s te ro ls in the ir 
me mbran es, and it is hypothesized th:tt toxicity to human ce lls is cau sed by a s imilar mechanism. 
Treatm e nt is s tarte d with an infu sion (If 1 to 5 mg o f A mphote ricin B pe r day, whi ch is g r<'ldually 
in creased to 0.65 mg/ kg dail y, with resu lt a nt pea k plasma levels of 2 to 4 ,u.g/ml. These levels can be 
nn int a incd du e to the re lative ly lo ng ha lf-life o f 2-t ho urs. The drug is e liminat ed \'C ry s lowly by th e 
kidneys with de tectable leve ls in th e urine fo r up to 7 wee ks aft e r discontinuation o f tn.: atm e nl. The re 
is little kno v.m concerning distribution int o the ti ss ues a nd me tabo lic pathways. Amph ote ricin B is 
recomme nde d only fo r patie nt s with progressive a nd po te nti a ll y fatal funga l in fec tio ns such a:-. 
crypt ocncco~ i s, di s<;e minated candidiasis. coccidio ido mycos is, and histo plasmosis. Due to th e ma ny 
ad\·ersc reacti o ns that frequently occur among those rece iving tre atm e nt , the usc of the drug is 
limited. The most comm only occurring react ions arc : feve r, headache , anorexia a nd we ight loss. 
Altho ugh no t as commo n, damage to the liver a nd kidneys, whic h may be pe rma ne nt , can occur. Fo r 
these reasons it is only administe red in hospitals whe re appro priate mo nit o ring fo r adverse side 
e ffects is provided . Until recentl y, Amphoter icin B WJS Jbout the on ly option in the case of life-
threatening funga l diseases (5) . 
In the experime nts perform ed by A bruzzo e t al. on the effects of a ntifungal agents on the CL 
response, Amphotericin B was found to s ignificantly reduce the CL response at a leve l of 1.25 ,u.g/ ml 
( 1,2). In the previously described experime nts by Johnson, Amphotericin B impaired phagocytosis in 
I o f the 2 do no rs s tudie d (17). Pre -trc;:1tment of blastospo rcs showed no significant increase in 
killing. In additio n to Ketoconazolc, Marm e r and his co lle ag ues studied the effects o f A mpho te ricin 
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£3 and Amph otericin B methyl es ter, £1 wate r soluble de ri vative of Amphot ericin B, on neutrophil 
functions both in l'il 'o and in vitro ( l9). Amphoterici n 8 and Amphote ricin 8 methyl es ter 
significantly inhibited migrating neutrophils and the CL response in incubations longe r than 15 
minutes and had no effect on phagocytosis or intracellular killing of bacteria. Tarnvik and Ansehn. 
from the Medical School at Linkoping, Sweden, eva luated the effects of Amphotericin B on 
lvmphocvte Sl imulation (23). Lymphocytes were obta ined from the venous blood of healthy donors 
and were adjusted to a concentrat ion of l X 106 ce lls/mi. The lymphocyt es were st imulat ed hy th~ 
addition of phytohemagglutinin (P HA), conca navalin A (con A), pokeweed mitogen (PWM ), and 
purified prot e in-derivative tube rculin (PPD ). Th ey were th en in cubat ed at 37C for 3 to.+ (PHA, co n 
r\) or 6 to 7 (PPD, PWM) davs. Mixed lymphocyt e cultures were also prepared by adding eq ual 
numbers of lymphocytes from 2 different individuals and incubnting th em for 6 to 7 days without the 
addition of any .s timulants. Four hours before the end of in cubation 0.4 J.1.Ci of 31HI-thymidine \'-'as 
: ~<Jd ed to C<J ch culture. The cuiiUrcs were washed onto g l;1ss fib~r filters, placed in 10 rnl ~c intill a tion 
lluid and co unt ed on a scinti llation counter. Concentrations at and above 4 J.lg/ ml of Amphotericin 
8 ca ust:d significa nt reductions in the incorporation of triti.J.ted thymidine irr esp~:ctive of th e 
stimulant used. 
Vecchiarell i and colleagues at the University of Perugia, Perugia, Italy performed several 
experim ents to evaluate the in vitro and in l'ivo effects of Amphote ricin Bon mouse splee n cells (26). 
In one experimentS week-old CD2Fl mice were given" single 10 mg/ kg dose of Amphotericin Bat 
1, 2, 4, 6, 8 or 12 days prior to an intravenous challenge of I X 106 cells of C. a/bicalls in 0.5 mi. Ten 
animJis were challenged in each group which included non-trented controls. All anim als died in the 
non-treated con trol group and in the 12 day prior-to-challenge group with mean survival times of .+.5 
.1nd 5 days respectively. Only 1 animal died in the 1 day prior-to-challenge group with a mean 
survival time of> 60 days. Two an im als died in the 2 and 4 day prior-to-challenge groups, both with 
mean survival times of > 60 days. In the 6 and 8 day prior to cha llenge groups 3 anima ls died, with 
mean sun·ival times of > 60 days. Vecch iarelli stat ed that these expe rimental results demonstrated 
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sign ifica nt leve ls of protection agJinst C. albicans infec tio ns with doses of A mphote ricin B at tim e 
periods that could not be expected to off a any direct che mothe rapeuti c e ffects. This may not be the 
c:1sc as you consider the ha lf-li fe of t he drug being 2-l hours and treatment o f huma n subjec ts a t 0.65 
mg/ kg resu lt s in se rum levels of 2 to -l J..Lg/ ml. These a nim a ls were treated \vith fift ee n tim es the 
dose no rm nlly give n to hum ans and the refo re, even a ft er al lowing a fas te r rat e of me tabo lism o f th l' 
d rug in m ice, it is possible to have a thera pe utic level o f drug in the se rum fo r several days. Yo u mus t 
~t l so take int o account the fac t tha t this treatm ent is for prophylaxis of the discasl! and not to curl! it. 
In man y c::tses th e level of drugs needed to preve nt a diseJSC a rc mu ch lower th<Jn the level needed to 
cu re the sa me disease. In orde r to e lucida te the e ffec ts behind th ese res ult s. ad dit ional expe rim ent s 
we re ca rried o ut in l'itro to de te rmine the effec t of Amphote rici n B o n va rious e ffector-cell 
popuLt tions. Effecto r ce ll s we re fractionated by plastic ad he rence, nylo n column adherence, 
ca rbonyl-i ro n powder and m.1gnc t, tr C<Itm ent with anti -th e ta (a nti-Thy 1.2) se rum cont aining 
co mple ment a nd trea tme nt with anti · asia lo GMJ se rum with com plement. These procedures 
resu lted in dis tinct e ffe ctor-ce ll po pula tions with which to slUdy the effec t o f Am phote rici n B o n 
speci fi c effector-cell po pula tions. In one expe rim e nt , 2 X 108 cel ls of C. albicans were bhe lcd w·ith 
300 J,.L Ci of Na2-51c ro4 for 2 ho urs at 37C. Various conce ntratio ns of e ffecto r ce lls \~,-·e re incubat ed 
with 5 X LO-l ce lls o f C. albicans for 4 ho urs, a ft er which co unts o f chromium re leased into the 
su pe rna ta nt were counted to de te rmine the degree o f lysis of the yeast. In a sim ilar expe rime nt , 
un labe led yeast ce lls we re incubated for 1 or 4 hours, plated out , and count ed to dete rmine the 
number of cells actually ki lled by the effector cells. Another experiment was perform ed in which 
phagocytic ce lls were incubated in the presence of 5 X 106 ce llsjml of C. ablicans fo r va rio us tim es. 
The ce lls were stained and the num ber of yeast ce lls phagocytized was de te rmined. The in 1•itro 
result s of the va rious fracti onated cells obt ained from anim als dosed with 10 mg/kg 8 days before the 
assay, showed that the treated plastic adhe rent cells had an increase in act ivit y o f 2 to 4 times that of 
the untreated pl astic adherent ce lls. Plastic nonadherent ce lls, nylon wool adherent cells and 
ca rbo nyl- iro n + magne t-treated ce lls all showed a decrease in acti vi ty. Ce ll popul at ions treated with 
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anti·thy 1. 2 and anti·asialo GMl plus comple me nt shov.'e U ove ra ll increases in activit y. These resu lt s 
suggest t hat Am photericin 8 stimulat es macrophages fo r e nh a nced activit y in the candidacidal assays. 
Summary 
The recent ri se in fungal infecti ons, and especi:-tl ly those that are life threat e ning, have bee n 
due to the inc r ~.;asc in immunocompromised patients. M:1ny resea rche rs have acknowledged the 
import a nce of cvn luating the effect o f antifungal agents on host immun ity, especially in the 
immunocomprom ised host. It is therefore inte resting to no te thnt none of the previously discussed 
resc;~rch has been perfo rmed in an immunocompromiscd model. Kn owing how 3tHifu ngal age nt s 
inte ract with the immune sys te m could be in va luable in select ing the appropriate agen t fo r the 
treatment of ct particu iJr disease in a part icul a r immunocompromised patient. The r ight cho ice of an 
antifungJ I agent for the rapy could determine whe th er o r no t the treatm e nt is successrul and could 
make the difrcrc ncc between lire and death in some patie nt s. 
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~ l ATE RIALS AND ~IETI I ODS 
l -and H-L~·mpiHH.')1~ Prolifera tion Assays 
J\bl c Bal b/c mice, 9 - 10 weeks of age, were obta ined from Si monsen Laborato ries, Gilroy, 
Cali fornia , and housed in shoe box cages with corn-cob bedd ing. Mice were housed at a maximum of 
5 mice per box, were fe d Rode nt Blox (\Vaync Pet Food Divis io n, Chicago, Il linois) a nd give n water 
al lihiwm. Some animals received a si ngle 200 mg/ kg J.P. dose o f cyclophosphamide (Sigm ~t 
(]H;mical Company, St. Louis, Missouri) 7-8 days prior to spl een re mova l for in vitm testing. OtiH.:r 
;nimals n.:cc ivcd 25 mg/ kg cyclosrnrinl: (Sand lmmum:; Sa nd oz Pharmaceu tica ls Co rpora tio n, East 
J- ;movc r, New J e rsey) I.P. at 2-J and ..JS hou rs prio r to splee n removal for in l'itro tes ting. 
On the day of in \'itro testing, mice we re c uthanizcd with C02, a nd the splee ns were remO\'Cd 
a.c ptically and placed into centrifuge tubes containing RPM I-t640 ( RPMI ) me dium (G IBCO 
LdJorat orics, C lwgr in , Ohio). Splee ns, poole d from 5·10 :111imal.s, were placed in a steril e whirlp:..~k 
b1g (Co nsolidat ed PIJstics Company Inc .. Twinsburg. Ohio) con taining 5 - 10 mls of RPM I. Th e 
sr lce ns \\ .. ere cu t in half a nd ro lled, us ing a rubbe r pr inting roller, until the spleen ce lls we re pressed 
o il. Th e cells we re washed twice in 10 ml of RPM!, and the red blood ce lls we re lysed by hypotonic 
ly:. is in which the ce ll s we re suspe nde d in 9 rnl distilled wat e r for no longer th an 15 seconds, after 
wt ich l ml of !OX phosphate buffe red sa line (PBS) was added. The cells were ce ntrifuged and 
ns us pended in 5 ml of RPMI-1 640 containing 2-mercapt oethanol (Sigma C he mical Company), 
scd ium pyntvat e (G IBCO Laboratories), and 20% fetal bovine serum (FBS ; H yclone Laboratories, 
Loga n, Utah) (mouse media). The ce lls (>9Y"7o viability) were counted o n a he macytometer and 
diu te d to appro priate concentr:Jtio ns in mo use me dia. 
Ke toconazole (S igm a Chem ica l Company), Fluco nazole, ( Pfizer Ltd. , Sandwich, Ke nt , 
U1itcd Kingdom) a nd ltraconazolt: (Jansse n Resea rch and D evelopment, Ne w Brunswick, New 
Je-sey) we re dissolved in acidified po lyethylene glycol (PEG; J.T. Baker C he mica l Company, 
Plillipsburg, New .J e rsey) and diluted imm ediately in RPM I cont a ining 2% PEG . Concentratio ns of 
1-l 
:'2. 16. ~- -l and 2/.lg/m l were made, which resulted in Gnal concen trations of 16, 8, -l, 2. and lf.lg/ml 
after thl' drug was mixed with spleen cells. Media contained a final concentration of 1% PEG. 
Mouse media used for T -cell prol iferati o n studies contained 1:100 dilution o f 
['hy10 he magl utinin (PHA ) stock so lution (G IBCO laborat ories) . Mouse media used for 8 -cell 
rrolifcration studies contained 5 ,ugj ml lipopolysaccharide (LPS; Sigma Che mical Co.) . One 
lund re d microlite rs of a splee n cell suspension containing 5 X 106 ce llsjml a nd 100 ,ul of each drug 
d lwion were pi petted into triplicat e we lls of a 9() well tissue culture plate (Falco n; Becton Dickinson 
Lthwarl' , Oxnard, C alifornia) and in cubat ed for 2-t hours nt 37C in 5o/rj C02. Each we ll was pulsed 
\lith 2 Ill (2 I!Ci) of mcthyl.3 H.thymidin e (New England Nuclear, Boston, Massachusett s), and the 
cd ls were incubated fo r an Jdditio na l 2~ hours. Following incuba tio n the ce lls we re harves ted onto 
g ~• ss filt er pa pe r (Filt e rmat; Skatron , Ste rling, Virginia), and the pape r was dried for a minimum o f 
U hours a t room te mperature. Disks were cut from the filt e r paper and placed in sci ntillation vials 
(~katron ) to which 2 ml of scintillation nuid (Scintivc rsc; Fi she r Scientific, S<Jnta C lara. California) 
w:rc added. The vials were cou nt ed on a Packa rd Tri -Carh 1500 Liquid Scintillation Analy-;r.;r 
(Cl)U it cr, H ialeah, Florida) to o btain counts per minut e (C PM ). 
Nttural Jo\illcr-Ccll Studies 
Me thods for immunesupprcssion of m ice, spleen cell pre paration and drug pre paration were 
id:nticalto those used for lymphoc}1CS prolifera tio n studies. Yac target ce lls fro m a Yae-l ce ll li ne 
(Pmcrican Type C ulture Collectio n, Rockville, MarylanJ), a Mo loney Leukemia virus-i ndu ced mouse 
lynphoma, were grown in mouse med ia at 37C in 5% C02. Approximately l X 107 cells in tO ml of 
R ' M I medium we re cent rifuged and all but 0. I ml of the supernatant was pi petted off. Ce lls were 
la ~cled by add ing tOO f.!l (100 !'Ci) of 51Sodi um Chrom ate (51Cr; New England Nuclear) and 
in tubating for I hou r at 37C in 5% C0 2. After incubation, th e Yac cells were resuspended in 5 ml 
FlS and centrifuged to remove unin corporat ed labeL The FBS was carefu lly removed, and the Yac 
ee ls were suspended in 5 ml o f mouse med ia. The cells were counted on a hem ac~tomcter and 
adusted to a concen tration of 2 X 105 cells / mi. 
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Fifty microli ters of Yac and spleen cell suspensions co ntaining l X 10~ and I X 10° cells 
respcclivelv (c ffce1or ccl l:largel cell ralio of 100:1) a nd 1011 J.LI of each drug dilulion were pipell ed 
into triplicate wells of a 96-well tissue culture plate. Wells containing Yac ce lls only and Yac cells 
plus 5% sa ponin (S igma Chemical Compan y) se rved as the spontan eous (lysis not associa ted with NK 
acti\·ity) and total release contro ls respect ive ly. The plat es were incubated fnr 4 hours at 37C in 5'3{ 
CO~. after wh ich 0.1 ml of the supernat ant was ca refully pipctted from each we ll and placed in 
scintillation vials containing 2 ml of sci ntillati on nuid. Vials were cou nt ed on a scin tillation counter 
for CP!\'1. Percent lys is was calcul:lt cd by dividing CPM from th e experim e nt lysis, minus the CPM in 
the spont <•neous release cont rol hy the CPM of the total release co ntrol. minus the CPM in the 
spon taneous lysis control , and multiplyi ng by 100. 
Test results were analy,.ed usi ng analysis of vari<~nce in a randomi:tcd block design. The 
exp ~ rim e nt s shcm.:ing significant res ult s (P < 0.01) we re further analyzed using Fish er's least 
significa nt Ji/Tc rence (P < 0.01) to determine concentrations that were signili ca ntly Jiffcrc nt from 
the wnt rols. Exper im ental va lues from 3 experim ent s (n =9) for cell prolife ration assays anti fr om 2 
cxptri mcnt.s (n =6) fo r natural killer ce ll assays were combined for the ana lyses. 
L.)' mplwt)1~ Viabilily Assay 
Mouse spleen cel ls, prepared as previously described, were Slimulaied wi1h LPS and 5 X 105 
ce lls were incubated in the presence of Ketoconazole, ltraconazole and Kctoconazolc, prepared as 
described above, a1 final eonccnlralions of lG, 8, 4, 2, 1 and 0 J.Lg/ ml for 48 hours al 37C in 5% C02. 
Fo llowing incubation spleen cell viabi lity was determined by trypan blue exclusion. 
1(, 
RESULTS 
E ll'~:l· t s uf An tifunga l Agents nn Cell Proliferati on 
K c t ocon ~tzo l c induced signific<Jnl reductions in uptak e of 3fHJ thymidinc by T and B 
lymphocytes in almost all immune models and experimen ts. In T-cc ll prolifl!ration studies 
KL"t oconazo lc induced significant red uctions as compa red to drug free controls beginning <JI I, 8 <HH.l I 
J.lg/ ml in Lhc norma l, cyclophosphamide-compromised and cyclosporim;-compromiscd models 
respectively ( Fig.!). In B-cell proliferation assays significant red uctions bega n at -1 ,8 and -1 !Lg/ ml in 
thc normal, cyclophosphamide-comprom ised and cyclosrorinc-comp romiscd models respectively 
( Fig. 2). Starting at I }J.g/ ml, ltr<Jtonazolc significantly reduced uptake of 3!H]thymidinc by bmh T 
and B lymphocytes in <JII models (Fig. 3 and -t ) . Fluconazole had no significant c ff(;ct on uptake of 
3[ H ]thymidin(; in cit he r T- or B-cc ll prolifcrat inn studies in any of th e immune models (Fig. 5 and 6). 
E IT~<:ts nf Antifungal Ag~nts 
o n Na tura l Killer-Cell Activi ty 
Kctoconazole hJd no sign ificant e ffect on natural killer ce ll act ivit y in any of the immun i.: 
models (Fig. 7). ltraconazole induced sign ificant reductions on natural killer ce ll activi ty in th (; 
imrnunc-norm:J I model beginning at I J.Lg/ ml. No effect w<.~ s noted in the other immunL' models (Fig. 
8) . Flu conazole appeared to have no significant effect on nntural killer-ce ll activity in any of the 
immune models (Fig. 9). 
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FIG. 1. Effect of ketoconazole concentration on uptake of 3[HJ-thymidine by T ceUs expressed as 
counts per minute in normal, cyclosporine-compromised (CY) and cyclophosphamide-compromised 
(CP) immune models. The means and standard deviations are shown. An asterisk (*) above a 
column indicat.es a significant difference (P < 0.01) from the controL 
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FIG. 2. Effect of ketoconazole concentration on uptake of 3[H]-thymidine by B ceUs expressed as 
counts per minute in normal, cyclosporine-compromised (CY) and cyclophosphamide-compromised 
(CP) immune models. The means and standard deviations are shown. An asterisk (*) above a 
column indicates a significant difference (P < 0.01) from the control 
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FIG. 3. Effect of itraconazole concent ration on uptake of 3[H]-thymidine by T cells expressed as 
counts per minute in normal, cyclosporine-compromised (CY) and cvclophosphamide-compromised 
(CP) immune models. The means and standard deviations are shown. An as terisk (') above a 
column indicates a significant difference (P < 0.01) from the control. 
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FIG. 4. Effect of itraconazole concentration on uptake of 3[H] -thymidine by B cells expressed as 
counts per minute in normal, cyclosporine-compromised (CY) and cyclophosphamide-compromised 
(CP) immune models. The means and standard deviations are shown. An asterisk ( ' ) above a 
column indicates a significant difference (P < 0.01) from the control. 
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FIG. 5. Effect of fluconazole concentration on uptake of 3[H]-thymidine by T cells expressed as 
counts per minute in normal, cyclosporine-compromi.sed (CY) and cyclophosphamide-compromised 
(CP) immune models. The means and standard deviations are shown. An asterisk (") above a 
column indicates a significant difference (P < 0.01) from the control. 
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FIG. 6. Effect of flu conazole concentration on uptake of 3[H ]-thymidine by B cells expressed as 
counts per minute in normal, cyclosporine-compromised (CY) and cyclophospharnide-compromi.sed 
(CP) immune models. Means and standard deviations are shown. An as teri.sk (")above a column 
indicat es a significant difference (P < 0.01) from the control. 
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AG. 7. Effect of ketoconazole concentration on lysis of Yac cells by natural killer cells in norm al, 
cydosporine -compromised (CY) and cyclophosphamide-compromised (CP ) immune models. The 
me1ns and standard deviations are shown. An asterisk (•) above a column indicates a significam 
dift: rence (P < 0.01) from the control. 
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FIG. 8. E ffect of itraconazole concentration on lysis of Yac cells bv natural killer cells in normal. 
cyclc;porine-compromised (CY) and cyclophosphamide-compromised (CP) immune models. The 
rnea1s and standard de\i ations are shown. An asterisk ( *) above a col umn indicates J significant 
diffex:nce (P < 0.01) from the control. 
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fi G. 9. Effect of nuconazole concentra tio n on lysis o f Yac ce lls by natu ra l killer cells in no rmaL 
cydosporine-comprom ised (CY) and cyclo phosphamide-comprom ised (CP) immune models. T ht.: 
ml:1ns and st:.tnd.:Jrd de\'iations a rc shown. An as terisk ("' ) above a column indicat es <1 signi!ic1111 
difcrcncc (P < 0.0 1) from the control. 
Ell:l·ts of :\ntifung::1l Agents on Lymph()(:_,1~ Viability 
Viability counts on LPS-st imu!a tcd lymph oc~tes following 2 d::~ys of incub~Hi on at 37C i11 5!( 
CC2 in the prese nce of 0. 1, 2. ·t 8 and 16 ,Ug/ ml o f Ketoconazole. ltraconazo le and Flucon:t7nk 
shewed that ltr~tconazole killed 85o/c. of l ym phoc~H~s at 1 ,L.Lg/ ml levels in l'iiro wit h up to a 9S'C. kill :tt 
the 16 ,Ug/ ml level. Lymphocy1es in cubated in the presence of Ketoco nazole had \·i<Jbili ty counts llf 
7Sr o f controls "t the I !lg/ ml bel with onlv 15% o f contro ls viable ot the 16 !lg/ ml bel. 
F!u·onazolc did not effect overall live c0unts which ranged fr om S7SC . 97% of controls (Table 1 ). 
TABLE I. Effect o f ketoco n;Jzolc. itracon;Jzolc Jnd nuco nazole concentration on viabilit y o f LPS 
!-. limul;ltcd l~rnphocytcs . Va lues arc shown as pcrcl:n tagc of viable ce lls in comparison with contrCll'i. 
Co ncc ntr;.llion (J..Lg/ ml) 
Drur ~ R lo 
Kc toconazole 78% 83% oS% ~7% J56Jo 
It raconazolc L5% 5% 1% JOb 267o 




II would appea r that Kctocon<trolc ca n be inhi bitory to T- and B- cel l prolifc.:rati0n at 
co nc<.:n trations Jtlainablc in serum (3.5 .Ug/ ml). Kctoconazole a l.so has a more inhibi tory cffc<.: t 
ilg<tinst T cells which are approxim ately ~-fold more sensitive to this agen t than B cells. Kctocon:t :to lc 
;dso appc~t r s to have a more profound effect on bOlh T <.tnd 8 celts in the untreat ed and Cyclosporin c-
treated anim<.~ l s than that which occurs in the Cyclophosphamide-t reat ed animals. These finding~ of 
the effects of Kctoconazolc on T- and B-ccll prolifera tion confirm the findings of expe rim ents 
performed by Buttke and Chopm an ( 1~ ). Se nior and S h aw(~~) and Gergely eta!. ( 16). 
ltraconazole induces sign ifica nt inhibitory effects on both T- and 8-ccl l prolife ra tion at 
approximat e leve ls to those attainable in se rum (0.6 .Ug/ml) and in tissues (up to 8 ,u.g/ ml) . 
Expcrirncnt :d data from Abru zzo ct al. {I) and .J ohnson ct al. ( 17) show no signi fi ca nt reductions in 
th.; ass: tys they performed, although thcsc assays we re nnt similar to ne ither T- and B-ccl l 
pwlil cration nor natural killer-cell assays. 
Fluconazole docs not appear to have any effects on the prolife ration of T or B cel ls at 
conce ntrations att ainable in serum {I ,Ug/ ml) . These conclusio ns are also supported by the wor k of 
Senior and Shaw (22). 
The e ffects of Ketoconazolc, ltraconazole and Fluconazole on lymphocyte-ce ll viability 
corrcbt c we ll with the reduct ions in ce ll prol iferation. Low lymphocyte viabilit y suggests th:H the 
reduct ions in ce ll proliferation are a toxic effect a nd not just a n inhibition of cell divisil )ll. 
ltraconazole's profound effect on murine T- and B-lymphocytc proliferation, while other researchers 
ha\·e foun d that Itraconazole has little if any effect on cholesterol synt hesis in hum an and ra t subj t.:c ts, 
may suggest another inhibitory mecha nism tha n that of blocking cholesterol biosynthesis {12). 
It docs not appea r that Ketoconazole or Fluconazole, at normal auai nable leve ls, have any 
effec t on natura l killer-ce ll activit y. It is int erest ing to not e that ltraconazolc induced signi fi can t 
reductions in percent lys is starting at l J.Lg/ ml in the immune-norma l model but had no effect on 
perce nt lys is in the immune-compromised models. Th ese results are co nt rad ictory with those of 
~~ 
Ccrgelv ct al. ( 16) who found th at Kctoconazolc at lc\·cls above 1 J..Lg/ ml inhibited natural killcr-cc ll 
ac ti' ity. This is probably due to the difference in the effector (huma n vs. murine ) and target (Yac \'S. 
K 5(.2) cells used. 
Som~ questions arc raised as to why Kctoconazo le and ltraconazole do not inhibit natural 
killer-c~ll activity to the same degree as they do lymphocyte proliferation. Some possible 
cxpbn;ttions arc that these drugs have J more toxic effect on proliferating cells than on non· 
prolif~.;r;tting cells, as in the case of m;my an tibiotics such as penicillin. Anothe r possible cxplan;•tiun 
is tlut the natural kille r assay is much short er (-t hou rs) than the lymphocyte prol iferat ion assays (-tS 
hours). Longer exposu re to The drug may he rcqu irctlto inhibit natur£tl kille r-cell acti vity. 
Eve n though cyclophosph:tmitJ c inhibi ts growth of all lymphocytes, it appears to 
prde renti:dly inhibit B cells whose thymidin e incorpor'-ltion were considerably less than the controls. 
Cyc lo:;porinc, on the other hand, hJs littl e or no effect on cell proliferation but significantly n.:duccs 
natur.:-tl killer-cell act ivity. 
Studies such as this one may he useful in determining which antifungal the rapy would be 
nw"tappropri: •te for patients undergoing a particular therapy that results in immunosuppression. It 
could he used to weigh a certai n (mtifungal agent's effi cacy in the treatment of a particu lar Jiscasc 
against any det rimental effect it m<~y have on the immune system. As immunology and antifungal 
dc,·ctopmcnt are still very dynamic fields, the full ram ifications of the immunologica l effects of 
;1ntifungals is yet to be determined. This knowledge m<ty make the difference between success or 
fai lure of an tifungal treatm ent , which in turn may make the difference between life ami dea th in cases 
of life- threa tening mycosis. 
Kctoconazole induces significant inhibitory effects on T- and B-ccl l prol iferation in immune· 
norm al and cyclosporine·compromised models, and has no significant effect on natura l kille r-cell 
act ivity at conce ntrations normally atta in able in serum . ltraconazole induces significan t inhibi tory 
effects on T and B cells in all immune models, and a lso induces significant inh ibit ory effects on 
natural killer-cel l activity in the immune-norm al mode ls at arproximate levels attainable in seru m 
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and :tt k\cls attai nable in tissue. Flu con ~uolc has no significant effects on neither T· and B· 
l~rnphoc~t~ proliferation nor on natural ~ilk:r ·ce ll ac tivit y. 
\Vhilc in l'itro results cannot be directly applied to in vii'O si tuations, it may he rossiblc tn usc 
in l'itm tes ting to aid in screening compounds that may have detrimental effects on the immune 
:-.ys tcm. Knowledge of the int eract ion of ant ifunga l agents \vith the immune system is li~ely tn 
become more increasingly important as the number of severely immun<>compromiscd pati ~..· nt s 
contin ues li) he on the rise. 
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APPENOIX 
Ex pt.·rimcntal D;\ta 
The follc)\ving tables give the exper imental rcsu lls for both cell proliferation st udies and 
natural killer cellJssays. 
Ct.'! I Proliferation- Ex periment # I 
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TABLE 2. Uptake of 3[HJ -thvmid ine expressed as cou nts per minute for ketoconazole at 0, I, 2, .J, 
~ <tnd IG .U.g/ml in immun e· normal, cyclosporine (CY) and cyclop hosp hamide (CP) immune-
comprom ised mode ls--T ce ll s 
Concentration (l'g/ ml) 
Model 4 16 
Normal Obs. #I .J1 7.j() 30-130 28672 17522 11848 .J52 
Obs. #2 37.J06 28756 25-1 18 15-188 85.JO 230 
Obs. #3 30 180 3829R 2.J97(, 18798 8226 20:10 
Mean 38.J.J2 32-195 26355 17269 9538 90.J 
S. D. 292 1 5095 2018 1669 2007 98 1 
CY Obs. #1 20798 12506 10814 6278 2460 602 
Obs. # 21694 14128 7882 5640 1788 3272 
Ohs. #3 24314 1 ~388 10%0 7182 1908 33.J 
Mean 22269 14007 9885 (,367 2052 1-103 
S.D. 1827 1445 1736 775 358 1624 
CP Obs. #1 32278 30970 34710 23156 10400 2432 
Obs. #2 33000 27526 21856 19260 16188 1550 
Ohs. 113 41!0(, 29588 2.~900 27712 10586 2190 
Mean 3546 1 2.~36 1 28489 23376 12391 2057 
S.D. 4902 1733 6437 4230 3289 45() 
3 1 
TABLE 3. Uptake of 3!HJ-thym idinc expressed as count s per minute for kctoconazole at 0, 1, 2, -k 
S ;n1d IG J.lg/ ml in immune-normal, cyclosporine (CY) and cyclophospham ide (CP) immune-
compromised rnodcls--8 ct:lls 
Concentration (J.Lg/ml) 
M ede l 8 l o 
i'!orm al Obs. #I 37980 32660 26426 18682 6684 942 
Obs. #2 27870 25424 23208 19994 86 18 84-l 
Obs. #3 34944 27128 27124 18 1.46 11948 346 
Mea n 33598 28404 286 19 18941 9083 7 11 
SD. 5 188 3783 32 13 95 1 2(,63 320 
CY Obs. #1 16926 13036 12350 6704 3246 2 16 
Obs. #2 15896 11396 0066 2386 400 
Obs. #3 1'!82(, 14710 9504 5592 2078 96 
Mean 17549 13873 11083 6 121 2570 237 
S.D. 2038 1184 1449 558 005 153 
C P Obs. #1 14196 14712 10330 11958 5388 2058 
Obs. #2 116 14 14878 10964 9848 41 56 21.42 
Ohs. #3 11962 14050 9958 4566 1424 
Mean 1259 1 14547 10417 10904 4703 1875 
S.D. 1401 438 509 1491 627 393 
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TABLE -1 Uptak~ of 3[H]-thymidine expressed as counts per minute for itraconazole at 0, 1, 2, ~ . 8 
and I(> 1--'g/ ml in immune-normal, cyclosporinc (CY) and cyclophosphamide (CP) immune-
compromised models--T cel ls 
Co ncentration (1--'g/m l) 
1\lodcl 0 2 4 8 16 
Normal Obs_ # I 35002 136 1520 ~82 58 132 
Obs_ #2 ~1 65~ ~0~ 1278 310 266 110 
Obs.#1 37374 19R 1504 (,0 91i 566 
Mean 38010 2¥J 1~54 284 140 269 
S. D. 337 1 1~0 154 212 Il l 257 
CY Obs. #I 28918 31i8 166 148 354 1216 
Obs.#2 20~1 0 ~ 1 6 1152 708 2160 270 
Ohs. #~ 16356 250 118 244 270 
Mean 21895 3~5 5 19 367 1257 585 
S.D. 0411 R5 550 299 1277 5-Ul 
C P Obs. #l 30948 3692 ll76 732 2510 456 
Obs. #2 38548 3604 3386 1336 1744 910 
Obs_ #3 1752 1330 11 16 908 6 1~ 
Mea n 3~748 3683 196~ 1061 1721 660 
S.D. 537~ 7~ 1234 306 801 230 
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TABLE 5. Uptake of 31H]-thymidinc expressed as counts per minute for itraconazolc <.t t 0, 1, 2, .f, 8 
:ond 16 J.Lg/ ml in imm une-normol , cyclosporine (CY) ond cyclophosphamide (CP) immune-
compromised models-- 8 cells 
Concentration (J.Lg/ml) 
~ l ode! 0 2 4 16 
Normal Obs. #I 40310 8054 832 406 426 528 
Obs. #2 40236 7492 3990 482 1476 622 
Ohs. #1 37fi72 fi50A 2404 256 2750 274 
Mean 3940() 737 1 2409 381 1551 475 
S.D. 1502 750 1579 115 1164 180 
CY Obs. # 1 17650 2524 680 1002 708 414 
Obs. #2 17066 4130 804 334 250 176 
Ohs. #1 19552 2378 -190 ~22 3R2 216 
rvlcan 18089 301 1 658 586 447 269 
S. D. 1300 972 ISS 363 236 127 
CP Obs. #l 11642 7924 3990 482 1476 622 
Obs. #2 9956 5094 2898 1858 101 8 728 
Obs. #3 13732 0012 3302 888 940 618 
Mean 11777 6343 2849 1488 952 656 
S. D. 1892 1444 480 524 6 1 62 
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TAB LE 6. U pwkc o f 3[HJ-thymidinc expressed as cou nt s per minute for nuconazole at 0, 1, 2, 4, 8 
an d 16 J.Lg/ ml in immu ne-nor mal, cyclosporinc (CY) and cyclophospham ide (CP) immune-
com promised modelS·· T ce ll s 
Concentration (J.Lg/ml) 
Mod el 0 16 
Norm al Obs. # 1 41446 38754 42030 38070 31880 3522 
Obs. #2 39178 39376 40232 32552 31530 6004 
Ohs. #3 38152 3~838 35226 38498 27092 4234 
Mean 39592 39323 39163 36373 30 167 4587 
S. D. 1686 544 3526 33 11i 2669 1278 
CY Obs. #I 21332 4226 20170 21610 15774 1922 
Obs. #2 22958 14670 21816 22 162 15828 2 1 1~ 
Ohs. #3 24270 24032 28520 19148 17682 1776 
Mean 22853 14309 23502 20973 16428 1942 
S.D. 1472 9908 4423 1005 1081> 177 
CP O bs. #I 45276 40764 44192 44506 10400 1L730 
Obs. #2 33348 47492 43934 34510 29138 8612 
Obs. #3 25434 49676 31058 31i276 32422 13470 
Mean 34686 45977 39728 38431 23987 11271 
S.D. 9988 4645 7510 5335 11 880 241)1 
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T AB LE 7. UptJkc of 3[HJ-thymidinc expressed as counts per minute for nuconazolc at 0, 1, 2. -l , 8 
:>no 1o Jlg/ ml in immune-normal, cyclosporine (CY) and cyclophosphamide (CP) immune-
compromised modcls-- B cells 
Concentration (llg/ml) 
Model 4 IIi 
Norm al Ohs. #I 36680 34066 34994 37716 41778 25962 
Obs. #2 34560 33666 28260 37 190 38350 44084 
Ohs. #3 387 16 21728 37478 27090 372 1(, 38470 
Mean 36652 29820 33577 34 199 39 11 5 36 172 
S.D. 2078 7011 4770 5643 2375 9277 
CY O bs. #1 15202 13872 16260 14224 19684 13068 
Ohs. #2 15524 1741 8 13448 17738 2 1252 14730 
Ohs. #3 171 24 18482 1o752 17240 14848 1omo 
Mean 15950 1.6591 15487 1(,401 18595 14829 
S.D !(129 24Jl 1783 1901 3338 1813 
CP Obs.#1 15564 13326 10074 13840 11076 13734 
Obs. #2 13784 4810 18428 13242 16160 13784 
Ohs. #3 12978 11022 18170 12906 10940 14820 
Mean 14109 9719 15557 13329 12727 1411 3 
S. D. 1323 4405 4750 473 2973 6 13 
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Ctll Prolift:rati nn ~ Exp~riment #2 
TAB LES. Uptokc of 3[H[-thymidine expressed as counts per minute for kctoconazolc at 0, I, 2, ~. 
R :ond LG !Lg/ ml in an immune no rmal , cyclosporine (CY) and cyclophospham ide (CP) immune-
compromised models--T ce lls 
Concen trat ion (!Lg/ ml) 
1\lndcl () 2 8 1(\ 
NormJI Obs. #l 29190 17462 16320 ll580 7062 3806 
Obs. #2 22598 23906 14174 128 1~ 5866 2178 
Obs. #3 41600 16302 16776 8266 12708 2952 
~ 1 ea n 3 ll 29 !9223 15757 10887 8545 2979 
S.D. 9048 4097 1389 2352 3654 8 1~ 
CY Obs. #1 20016 11808 11964 13080 4350 13~2 
Obs. #2 19980 11918 12422 9468 4228 ~5~ 
Obs. #3 :10082 14322 1685(, 9252 4348 1140 
Mean 23359 12683 13747 10600 4309 2179 
S.D. 5822 1421 2702 2150 70 lo27 
C P Obs. #I 25582 17872 21228 1-1286 5880 7822 
Obs. #2 20700 22738 17592 20044 4934 
Ohs. #3 24270 16124 27356 23972 31186 2438 
Mean 24926 18232 23774 18617 19037 8398 
S.D. 927 2309 3193 4924 12683 3785 
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TA BLE0. Uptak e of 3[Hj-lhymidinc expressed as counts per minute for kctoconazotc at 0, 1, 2, -l , 
8 and 16 t"g/ ml in an immune norm al, cyclos porin e (CY) and cyclophosph amide (CP) immune-
compromised modc ls-- B ce lls 
Concent rat ion ( t"g/ ml) 
,\ Jodcl 0 2 4 8 16 
Norm;;d Ohs. # I 34400 31097 385 11 28365 13375 4705 
Obs. #2 36995 325 15 34109 21473 13553 2565 
Ohs. #3 37341 14087 326 19 18873 10847 1911 
Mean 36278 32566 35080 22904 12592 3060 
S.D. 155 1 1496 3004 4905 1514 1461 
CY Obs. #1 42655 476 15 35793 27101 15245 3993 
Obs. #2 502 17 40317 40811 23443 1827 1 2899 
Ohs. #3 46285 :187 11 :18025 26599 16461 2829 
Mean 46366 42214 38210 257 14 16659 3240 
S.D. 3782 4746 25 14 1983 1521 653 
CP Obs. #1 5855 6637 9703 3907 2719 U 97 
Obs. #2 8555 5919 8817 6153 3635 1561 
Ohs. #3 9177 9681 7631 4883 3997 1355 
Mean 7862 7412 8717 4981 3450 1471 
S.D. 1766 1007 1040 11 26 659 105 
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Tr\BLE 10. Uptake of 3!HJ-thymidinc expressed as counts per minute for itraconazolc at 0, 1, 2. ~. 
~ ~1nd 16 J..Lg/m l in an immune normal, cyclosporinc (CY) and cyclophosphamide (CP) immune-
compromised modc ls--T cells 
Conccn\ration (llg/ml) 
Mndc l 0 \6 
Norma l Ohs. #I 26022 2388 288 814 1458 2452 
Ohs. #2 32916 12712 1264 536 2168 706 
Ohs. #3 36098 24-16 346 340 694 1380 
Mea n 31679 5849 633 563 1440 1513 
S.D. 5 151 5944 548 238 737 88 1 
CY Obs. #J 14488 670 1002 366 5622 160 
Obs. #2 28700 4060 3996 3850 1170 1616 
Ohs. #3 24072 2788 \830 7o30 2032 212 
Mean 22420 2506 2276 3949 294 1 663 
S.D. 7249 1713 1546 3o33 2361 826 
CP Obs. #1 15180 902 952 954 4022 1182 
Obs. #2 5962 2064 1946 6144 1488 1766 
Ohs. #3 25452 \832 2612 900 7 154 2414 
Mean 15531 \619 1837 2666 4221 1787 
S. D. 9750 581 835 30 12 2836 616 
3'J 
Tr\B LE II. Uptake of 31HHhymidinc expressed as cou nts per minmc for itraconazole at 0, 1, 2, -l, 
X and 16 J.lg/ ml in an immune normal , cyclospo rine (CY) and cyclophosphamide (CP) immune-
comp romised models--B cells 
Conce ntration (J.lg/ml) 
Mode l 0 8 16 
Normal Obs. #1 27093 10729 -1985 1527 1041 1607 
Obs. #2 3-1591 10-155 4035 1873 791 1593 
Ohs. #3 3150 1 1-1673 5087 745 1305 1627 
Mean 31062 11 952 -1702 1382 1046 1609 
S.D. 3768 23(,() 580 578 257 17 
CY Obs. # I -1686 1 1-1983 3877 979 1223 1661 
Obs. #2 53359 12837 -1939 9257 6151 2099 
O bs. #3 5 1629 14529 2729 4573 4212 1779 
Mean 506 16 14116 3848 4573 4121. 1779 
S. D. 3365 1131 1105 -1245 2576 280 
CP Ohs. #1 5173 6283 6517 2721 2299 2941 
Obs. #2 4463 5695 4159 3367 1467 2835 
Obs. #3 11 273 5107 3243 1533 104~ 1337 
Mean 6970 5695 4640 2540 1604 2371 
S. D. 3744 588 1689 930 638 897 
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TABLE 12. Uptake of 3!H \-I hymidine expressed as counts pe r minu te for lluconazole al 0, I, 2. 4, 8 
and 16 .Ug/ml in an immun e normal, cyclosporinc (C Y ) and cyclophosphamide (CP) immune-
comprom ised modcls--T cells 
Concenl ratio n (1-Lg/ ml) 
!\,todd 0 2 4 8 16 
Normal Obs. #I 29462 21836 22952 21392 28280 289 16 
Obs. #2 l%1i6 22628 21906 40208 24256 20728 
Ohs. #3 2564-l 21550 2MR-l 17716 31602 30-178 
Me<.~n 24924 22005 23781 26439 28046 26707 
S.D. 493R 55R 2399 120ti5 3679 5237 
CY Obs. #I l9156 19906 14414 22288 2032ti 22792 
Obs. #2 21510 221M 23116 197-12 24606 26998 
Ohs. #3 25-192 9328 27904 2.t~32 2-l-124 3-1132 
MC<:Hl 22063 17 126 21811 22 121 23ll9 2797-l 
S.D. 3201 6845 6839 2300 2420 57:B 
CP Obs. #I 22074 20360 14788 12452 22036 18862 
Obs. #2 25390 33320 20630 31024 25238 15422 
Ohs. #3 20 154 22392 25ti28 28400 3 11 86 252 18 
Mean 22539 25357 20349 23959 26 153 1983-l 
S.D. 2ti.J9 W70 5425 1005 1 4M3 4970 
-II 
TABLE 13. Uptake of 3[H[-thymidinc exp ressed as counts pe r minute for nuconazole at 0, I , 2. -1, ~ 
and 16 J.Lg/ ml in an immune normal, cyclosporinc (CY) and cyclophosphamide (C P) immune-
compromised rn odels--B cells 
Co ncentration (!Lg/ ml) 
~ l ode! 0 2 8 16 
Norm:ll Obs.#l 38711 36627 39379 3368 1 3 1885 36203 
Obs. #2 30249 33867 35259 41403 32699 -11205 
Obs. #3 3 1961 334 19 37045 3~7 11 39613 30045 
Mean 33640 3-1638 37228 36932 34732 35818 
S. D. 4-174 1737 2066 -1003 4246 5590 
CY Obs. #I 39709 59683 53043 58801 -1 3649 -13573 
Obs. #2 -12-129 -1867 1 -180-19 -16027 5057 1 366-13 
Ohs. #3 54551 -16225 51197 59291 45(,03 -13301 
Mean -15563 51526 50763 5-1706 -16608 41172 
S.D. 6452 5853 20fi2 nl40 29 14 3205 
CP Obs. #1 8059 8213 6159 6059 8729 5-193 
Obs. #2 6737 7871 7911 6089 6367 5983 
Obs. #3 6165 6197 7453 7941 7227 7717 
Mean 6987 7427 7174 6696 7441 6398 
S.D. 793 88 1 742 880 97(, 954 
~2 
Ce ll Pro liferation- Ex periment #3 
TABLE 1~ . Uptake of 3fHJ-thymid ine expressed as coun ts pe r minute for ketoconazole J t 0, 1, 2, -L 
.Sand I61J.g/ml in im mune-normal, cyclosporinc (CY) and cyclophosphamide (CP) im mune-
compromised models--T cells 
Concentration (J.Lg/m l) 
1'vlmlcl 0 2 4 8 16 
0!orm;tl Obs. # I 337(>8 3(,(,(,~ 26248 2~584 9840 5698 
Obs. #2 392-16 31800 2~54 16828 1 1 ~26 5830 
Ohs. #3 4.~210 25242 35404 21506 ll836 4664 
Mean ~0408 3~589 28855 20973 1103~ 5397 
S.D. 7291 240R 5766 3905 1054 639 
CY Obs. # 1 21380 15~ 15272 9132 7654 5056 
Obs. #2 24886 20996 15010 10322 6644 1688 
Ohs. #3 39(,40 23~ 13772 JOG¥> 5686 1502 
Mea n 28635 19965 14685 10033 6661 27~9 
S. D. 9o90 ~089 80 1 797 984 2000 
CP Obs. #1 30452 22698 46578 14234 19854 4870 
O bs. #2 31524 25268 18 146 16424 9048 5202 
Obs. #3 41262 42758 37942 17788 19052 6300 
Mea n 34413 30241 3~222 16149 15985 5457 
S.D. 5956 10916 14576 10033 666 1 2749 
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TAB LE 15. Uptake o r 3!HI-thymidine expressed as counts per minute ror ke toconazole a t 0, 1, c, 4, 
~ :1nd 16 !lg/ml in immune- no rm al, cyclosporine (CY) and cyclophosphamide (CP) immune-
compromised modcls··B cells 
Concentration (llg/ml) 
\lndcl 0 8 16 
No rmal Ohs. # I 50904 41192 43104 45554 19806 1470 
Ohs. #2 58900 41882 45746 3~630 28360 4134 
Ohs. #"?. 39948 45230 27170 1727(, 5484 
Mean 4991 7 42768 -!4-!25 37118 218 14 7029 
S.D. 9514 2160 1ROR 9285 5808 3905 
CY Obs. #I 46704 53 158 38870 39346 21172 3454 
Obs. #2 50122 53610 45110 28540 24906 -1486 
Obs . #3 417:\o 25414 46194 ~~ 132 23884 4334 
M ean 401 87 -!406 1 43391 34006 23321 7425 
S.D. 4217 loi50 3953 5404 1930 ()00/i 
CP Obs. #1 2 1524 18482 23934 16610 8470 3424 
Obs. #2 17794 18684 17002 14068 10224 2896 
Ohs. #3 22524 2378(, 38678 12358 8634 3422 
Mean 20614 20321 26538 14345 9109 3247 
S.D. 2493 3003 11070 2140 969 304 
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TABLE If.. Uptake of 3!HJ-thymidinc expressed as counts per minute for itraconazole at 0, I , 2, -l-, 
H ;~nd J(, !lg/ ml in immune-normal, cyclosporinc (CY) and cyclophosphamide (CP) immune-
compromised models--T cells 
Concentra tion (!lg/ ml) 
~\ l nde l 4 8 16 
Normal Obs. #I 3583~ 776 3598 -W62 486 878 
Obs. #2 32438 1~8 1392 112 1602 1566 
Obs. #3 1270 358 328 190~ 2870 
Mean 3~136 1173 1783 163~ 1331 1772 
S. D. 2~01 357 1655 2~5 1 747 1012 
CY Obs. #I 375~ 2~26 5196 2504 1066 
Obs. #2 2532~ 1068 742 1178 1848 288 
01». #3 30014 115(, 872 1388 1228 1286 
rvtcan 32959 1550 2270 l2EG 1860 880 
S.D. (,(,5(, 760 2535 1~8 638 524 
CP Obs. #1 57256 2086 1~72 2530 1374 9028 
Obs. #2 40994 166 1730 1104 238 288 
Obs. #3 80800 2148 2656 1\08 74 946 
Mean 59683 1~7 1953 1414 95 3421 
S.D. 20014 1127 623 998 542 4867 
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TABLE 17. Uptake of 3!HJ-thymidinc expressed as counts per minute for itraconazo le at 0, 1. , 2, -1. , 
8 and 10 ,LLg/ ml in immune-normal, cyclosporine (CY) and cyclophosphamide (CP) immune-
comrrom iscd models--B cells 
Concentrotion (J.Lg/ ml) 
Model 0 2 4 16 
Normal Obs. # I 45 172 7652 3164 22-1.2 1338 840 
Obs. #2 50778 9672 3388 2483 1582 J44(, 
Ohs. #3 556 18 o500 3040 4R19 6622 5252 
Mean 50523 7941 3197 3183 3181 25 l3 
S.D. 5228 1600 176 1422 2983 2392 
CY Obs. #I 56422 10274 2670 1266 3792 5480 
Obs. #2 44120 8984 6096 4268 4956 2600 
Ohs. #3 5635(, J1 o26 4692 3086 3600 o036 
Mean 52299 10295 4486 2873 4138 4705 
S.D. 70R4 1121 1722 1512 7 11 1844 
CP Obs . #I 14860 5490 5030 2212 2186 1734 
Obs. #2 18334 9618 3654 1660 1308 
Ohs. #3 15370 8798 4590 1580 3248 3430 
Mea n 16188 7969 4425 1896 2365 2157 
S.D. 1876 2 185 703 44(, 809 1123 
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TABLE IS. Uptokc o f 3[H[-thymidinc expressed as counts per minute for Ouconazole at 0, 1, 2, 4. 8 
:~nd \(, !'g/ ml in immune-normal , cyclosporine (CY) and cyclophosphamide (CP) immune-
compro mised models··T cells 
Co ncentration (l'g/ ml) 
Mode l 0 4 1o 
Norm.1l Obs. # I 17056 33236 27674 41618 46970 51640 
Obs. #2 43386 34342 35480 34004 39420 35654 
Ohs. #3 51462 159~2 491 1iS 3:..122 00976 59372 
Mea n 3730 1 34520 37441 36381 491 22 48889 
S.D. 14690 11 28 RRS4 3708 893 1 9876 
CY Obs. #1 198 16 308 18 29144 26530 28472 23840 
Ohs. #2 25660 240 14 27736 23 134 24052 21 138 
Ohs. #3 349~0 36464 300\4 35570 32818 39390 
Mean 26809 30432 30965 28413 28447 28123 
S. D. 7ti32 6234 4429 (,413 4383 9851 
CP Obs. #1 34088 56196 37946 26888 29350 30458 
Obs. #2 32896 31014 31902 3 1590 36076 43888 
Ohs. #3 31168 39022 38906 404 14 48592 32428 
Mean 32717 42077 36251 32964 38006 35591 
S.D. 1199 10505 3100 5007 7973 5921 
~7 
TABL E 1~. Uptake of 3JHJ -thymidine expressed as co unts per minute for nuconazolc at 0, l, 2. ~ . 8 
:tnd 16 .U.g/ml in immune- normal , cyclosporinc (CY) and cyclophosphamide (C P) immune-
compromised models--B cells 
Concentration (l'g/ ml) 
~ l ode \ 0 2 4 8 ](i 
Nm m;-11 Obs. #1 39106 ~9696 ~400 37959 50214 52940 
Obs. #2 47480 45572 46238 51770 47128 ~7022 
Obs. #3 43008 ~2700 49288 ~9632 50246 43928 
Mean ~3 1 98 ~5989 47975 46454 491 96 47963 
S.D. ~1 90 35t7 1509 7~34 179 1 4579 
CY Obs. #1 5590~ 51200 52150 5~38 52040 55302 
Obs. #2 5 1992 56068 ~922 55552 50778 52082 
Ohs. #3 53094 ~7042 55824 46240 44336 77358 
Mean 53663 51637 52290 52077 ~905 1 6158 1 
S.D. 2017 4230 3~53 5085 ~132 13758 
CP Obs. # 1 14552 17688 12666 17582 15336 17808 
Obs. #2 15134 19028 21736 20270 13386 20658 
Ohs. #3 l5461i 17104 23424 20504 17256 1841 8 
Mean 15051 17940 19275 19452 15326 18961 
S.D. 4()3 986 5786 1 62~ 1935 1501 
~8 
Natural Killer Cell ,-\ssa)' 
Expt.·rimcnt # I 
TABLE 20. Pcrc~nllysis for kctoconazolc at 0, 1, 2, 4, 8 and lG .U.g/ml in immune-normal, 
cvclosporinc (CY) and cyclophosphamide (CP) immune-compromised mode ls. 
Concentration (1-Lg/ ml) 
Model 0 2 ~ 8 16 
Nnrmal Obs. #I 1 8.2~ 13.07 16.99 2~.78 18.21 9.23 
Obs. #2 16.85 13.08 14.19 12.56 15.36 15.17 
Ohs. #'l, 1~.m 17AR 10.30 Jo05 17.52 16.81 
Mean 16.60 14.54 13.85 17.80 17.03 13.74 
S. D. 1.7'! 2.5~ 3.33 ().29 us 3.98 
CY Obs. #1 7.07 20. 12 4.49 12.98 5.66 2.77 
Obs. 112 -2.21 10.66 10.15 8.05 7.20 6.80 
Obs. #3 13.16 0.6B 8.46 0.5 2.80 0.14 
Mean 6.01 10.49 7.70 9. 17 5.22 3.23 
S.D. 7.7~ 9.72 2.90 3.38 2.23 3.36 
C P Obs. #1 14.85 11.83 12.32 1~.3~ 5.28 15.23 
Obs. #2 19.17 22.68 10.44 -0.82 21.33 ~.23 
Obs. #3 11.07 19.00 22.01 19.79 21.22 14.65 
Mean 15.03 17.84 14.92 11.10 15.94 11.37 
S.D. 4.05 5.52 7.70 JO.o8 9.23 6.19 
4~ 
TABLE 21. Perce nt lysis for itraconazolc at 0, 1, 2, 4, 8 and 16 ~-tg/ml in imrnunr..:-normal , 
cyclosporinc (CY) and cyclophosphamide (C P) immune-compromised models. 
Concentration (J.Lg/ ml) 
~ l ode ! 0 2 4 16 
No rmal Obs. #I 17.10 11.94 7.44 7.24 6.05 5.29 
Obs. #2 18.98 8.50 12.3 1 1.52 8.44 
Obs. #3 23.2() 15.68 17.95 14.85 1.51 2.86 
Mean 19.78 13.81 11.30 !1.46 3.70 5.53 
S.D. 3.16 2.64 5.79 1.87 2.27 2.80 
CY Obs. #I 8.47 3.04 5.84 2.69 3.81 3.27 
Obs. #2 3.61 7.86 6.48 6.34 6.98 1.39 
Ohs. #3 9.95 7. 15 1.79 4.09 2.5-t 2 94 
Mean 7.34 6.02 4.71 4.38 4.45 3.20 
S.D. 3.32 2.60 2.54 1.84 2.28 0 .24 
C P Obs. #I 28.54 18.98 22.21 14.31 16.40 
Obs. #2 21.36 22.73 5.68 10.60 12.38 
Ohs. #3 19.85 16.00 -1.02 15 .10 12.37 15.41 
Mea n 23.25 19.24 10.56 15.03 13.12 13.90 
S. D. 4.04 3.37 16.42 0.69 2.97 2.14 
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TABLE 2c. Percent lysis for !luconazo lc at 0, 1, 2, 4, 8 and 16 J.Lg/ ml in immune· norm al. 
cyclosporinc (CY) and cyclo phospham ide (C P) immune-comprom ised models. 
Concentratio n (J.Lg/ ml) 
~ l ode I 0 2 ~ 8 16 
No rma l Obs. #1 17.31 18.00 13.39 9.52 12.49 10. 12 
Obs. #2 18. 10 7.67 16,02 11.20 16.00 13.13 
Ohs. #3 1 n~ 1o.s2 9.31 10.63 12.90 12.67 
M ean 16.59 1~.16 12.90 12.45 13.82 11.97 
S.D. 1.98 5.66 3.38 3.71 1.91 1.62 
CY Obs. # I 9.54 7.2 1 8.38 8.47 11.68 8.21 
Obs. #2 8.49 0.35 3.80 -0.50 7.93 7.62 
Ohs. #3 -O.ol 7.6 1 -1.83 7$8 10.82 0.92 
Mean 5.8 1 5.06 3.45 5.28 10.1~ 7.59 
S.D. 5.58 4.08 5.1 1 5.02 1.97 O.li5 
CP Obs. # I 11.53 15.97 20.09 13.08 a19 13.69 
Obs. #2 28.25 17.74 22.48 22.59 5.75 17.05 
Ohs. #3 26.18 2 1.97 18.31 1 ~ .56 19.93 19.53 
Mc;.m 21.99 18.56 20.30 16.74 13.29 16.76 
S.D. 9. 11 3.08 2.09 5. 12 7. 13 2.93 
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Natu1·al Killer Ct' ll Assay 
Ex prrintl'nt #2 
TAB LE 23 Percent lysis for ketoconazole al 0, l, 2. -t, 8 and 16 ,ugj ml in immune-normal. 
cyclosporinc (CY) and cyclophosphami de (CP) immune-compro mised mode ls. 
Concentration (1-Lg/ml) 
:'vlodel 0 2 8 16 
Norm;d Obs. II' I 62.68 56.30 61.72 ~7.37 ~7.37 58.2 1 
Obs. #2 57.58 54.07 53.11 6304 43.86 93.94 
Obs. #3 39.o7 ~. I R (>6.83 o2.16 50R8 ~2.90 
Mea n 53.1 1 51.52 60.55 57.79 ~7.37 65.02 
S.D. 12.42 6.45 6.93 9.05 3.5 1 26. 19 
CY Obs. # 1 18.G2 35.89 37.80 66. 19 27.9 1 37.48 
Obs. #2 39.71 44.50 20.26 t8.02 21.53 J7 .HO 
Ohs. #3 15.79 30.1~ 19.30 29.5 1 40.03 1 ~.51 
Mea n 2~.5 1 36.84 25.78 37.91 29.82 29.93 
S.D. 13.21 7.22 10.42 25.16 9.40 13.35 
CP Obs. #1 62.36 51.52 52.15 ~.18 45.45 ~1.63 
Obs. #2 24.08 19.30 21.63 0.80 20.89 29. 19 
Obs. #3 40.67 15.79 33.0 1 -U1 .73 30.46 45.77 
Mea n 42.37 28.87 35.57 30.57 32.27 38.86 
S.D. 19.20 19.69 15.47 25.81 12.38 8.63 
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TABLE 2~. Percent lysis for itraconazole at 0, 1, 2, ~ . 8 and lG J.Lg/ ml in immune·normal, 
cyclosporinc (CY) and cyclophospha mide (CP) immune-compromised models. 
Concentrat ion (1-'g/m l) 
il-l odc l 0 4 16 
Normal Obs. #1 51.52 H54 53.43 35.25 48.64 39.39 
Obs. #2 ~0.67 62.36 59.49 ~3.86 ~7.37 50.88 
Ohs. #3 ~5.77 27.27 24.40 ¥>71 c2.04 30.¥> 
Mean ~5.99 ~.39 45.77 ~1.95 52.68 -10.2~ 
S.D. 5.43 17.56 18.75 5.98 8.13 10.21 
CY Obs. #1 37.80 H54 27.27 51.20 24.72 40.67 
Obs. #2 37. 16 ~ 1.3 1 37.48 39.39 48.96 22.17 
Ohs. #3 15.4 7 25.68 29.R2 2153 29.19 55.98 
Mean 30.1~ 36.84 3 1.53 37.37 34.29 39.6 1 
S.D. 12.71 9.72 5.31 1~.9~ 12.90 1f>.93 
C P Obs. #I 62.68 33.01 36.20 33.33 27.19 40.67 
Obs. #2 40.03 27.27 33.33 13.88 31.74 22.17 
Obs. #3 34.6 1 34.93 323S 36.20 26.32 55.98 
M c<.J n 45.77 31.74 33.97 27.80 28.65 39.6 1 
S.D. 14.89 3.98 199 12.15 2.79 16.93 
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TABLE25. Perce nt lysis for nuconazolc at 0, t , 2, 4, 8 and 16 ,U.g/m l in immunc·norm JI. 
cyclmpori nL: (CY) and cyclophosph amide (CP) immun...-:-compromiscd models. 
Conccnlralion (!Lg/ml) 
Model 0 2 ~ 8 16 
Norma l Obs. #I 56.30 57.26 59.49 57.58 61.72 63.96 
Obs. #2 59.49 58.53 74.48 55.66 ~.1 8 28.55 
Obs. #3 5(,.9~ 48.% 53. 11 31i.R~ 5~.07 
Mean 57.89 57.58 60.98 55 A5 ~7.58 48.86 
S.D. 2.2() O.R4 12.82 2.24 12.78 18.27 
CY Obs. #1 40.35 37.48 31.74 38.44 40.99 3~.6 1 
Obs. #2 30.¥. 37.48 27.59 35.57 37.16 28.55 
Ohs. #3 9.73 21.70 27.91 79.59 16.75 I 1.96 
Mea n 26.85 32.9 1 29.08 5 1.20 31.63 25.W 
S.D. 15 (,3 7.92 2.11 nm 13.03 11.72 
C P Obs. #1 13.5(, 57.26 27.27 55.66 65.87 ~3.86 
Obs. #2 ~9.28 58.53 42.90 42.58 44.82 16.11 
Ohs. #3 30. 14 5(,.94 43.54 44.50 13.24 
Mea n 30.99 57.58 37.9 1 49.12 51.73 24.40 
S.D. 17.88 O.R4 9.21 9.25 12.25 16.91 
5~ 
Natural Ki ller Cell Assay 
Experimt' nt # 3 
TAB LE 26. Pcrccnl lysis for kctoconJzole a! 0, l , 2, 4, 8 and 16 ,U.g/ ml in immune-norm al. 
cvclosporinc (CY) and cyclophosphamide (CP) immune-compromised models. 
Conce ntratio n (!Lg/m l) 
Model 0 8 16 
Nnrmal Obs. #1 37.15 19.29 28.30 21.68 ~8.16 37.48 
Ohs. #2 16.51 I 1.95 14.90 11.17 11.67 fi.83 
Mean 26.83 15.62 21.60 lliA3 29.92 22.16 
S.D. 14.59 5.19 9.48 7.43 25.81 2 Lfi8 
C Y Obs. # I 2.27 7.00 12.95 -1.91 9.17 22.29 
Ohs. #2 IO.Iil 8.28 1.82 12. 17 13.84 8.~ 
Mea n 6.44 7.~ 7.39 5. l3 lL50 15.37 
S.D. 5.90 0.90 7.87 9.95 3.30 9.80 
C P Obs. #l 26.97 5.88 26.52 32.09 34.98 19.01 
Ohs. #2 7.66 o.ll 25.97 21i.l9 17.51 21.07 
Mea n 17.32 5.99 26.24 29.14 26.24 20.04 
S.D. 13.1i5 0.16 0.39 4.17 12.35 1.41i 
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TABLE 27. Percent lysis for itraconazole 0, I , 2, 4, 8 and 16 J.Lg/ ml in immune-normal, (CY) 
~nd cyclophosph<.lrnicle (CP) immune-compromised models. 
Concentration (J.Lg/m l) 
~ l odel 0 4 8 16 
Normal Obs. #1 30.66 36.17 36.08 17.65 12.32 18.86 
Obs. #2 37.20 19.72 22.82 29.97 28.68 20.07 
Obs. #3 31.00 11.2R 12.14 5.86 
M ean 32.96 27.95 29.45 19.64 17.71 14 .93 
S.D. 3.68 11.63 9.38 9.50 9.50 7.88 
CY Obs. #l 15.16 19.89 15.67 -0.43 18.60 27.47 
Obs. #2 3 1.95 26.18 14.98 2 1.70 21.53 13.95 
Ohs. #3 18.69 5.Rtl IS76 -l.-'6 o29 
Mean 21.93 17.31 15.47 8.6 1 15.47 20.7 1 
S.D. 8.85 10.41 0.42 11.61 8.09 9.56 
CP Obs. #I 23.08 29.54 20.84 25.06 22.82 20 .15 
Obs. #2 25.06 14.04 17.48 17.57 20.15 23.17 
Obs. #3 26.01 17.9 1 27.04 18.R6 3.44 lo.62 
M ea n 24.72 20.50 21.79 20.50 15.47 19.98 
S.D. 1.49 8.07 4.85 4.01 10.50 3.28 
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TABLE 28. Percent lysis for fluconazole at 0, 1, 2, 4, 8 and 16 ,Ug/ ml in immune-norm al, 
cyclosporinc (CY) and cvclophospham ide (CP) immune-compromised models. 
Concent ration (J.Lg/ml) 
Mode l 0 4 8 16 
Nnrrn~tl Obs. #1 21.3-1 23.12 17.70 15.55 14.06 19.0-1 
Obs. #2 36.55 37.29 34.55 -11.15 39.03 37.40 
Ohs. #~ 19.59 35.36 28.83 17.33 28.-12 9.76 
iv1can 32.49 31.92 27.03 2-1.68 27.17 22.40 
S.D. 9.78 7.69 8.57 1-1 .30 12. 1-1 14.62 
CY Obs. #I 16.-1-1 22.30 12.60 20.00 18.29 17.40 
Obs. #2 :25.3-f 20.82 13.62 20.30 15.25 15.62 
Ohs. #3 12.06 11.61 10.87 16.59 16.96 2:u9 
Mean 1.7.95 18.24 12.33 IR.96 16.83 18. 74 
S.D. 6.77 5.79 us 2.m 1.53 3.96 
CP Obs. #I 14.1-1 10.35 12.06 17.-18 10.58 13.5-1 
Obs. #2 12.2 1 6.86 8.57 17.85 8.79 14.14 
Obs. #3 17.11 17.03 7.98 16.44 
Mean 13.18 8.61 12.58 17.45 9.12 14.71 
S. D. 1.37 2.47 4.29 0.41 1.33 1.53 
